The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Injectable cryogel-based whole-cell cancer vaccines
Open accessAbstract
A biomaterial-based vaccination system that uses minimal extracorporeal manipulation could provide in situ enhancement of dendritic cell (DC) numbers, a physical space where DCs interface with transplanted tumour cells, and an immunogenic context. Here we encapsulate GM-CSF, serving as a DC enhancement factor, and CpG ODN, serving as a DC activating factor, into sponge-like macroporous cryogels. These cryogels are injected subcutaneously into mice to localize transplanted tumour cells and deliver immunomodulatory factors in a controlled spatio-temporal manner. These vaccines elicit local infiltrates composed of conventional and plasmacytoid DCs, with the subsequent induction of potent, durable and specific anti-tumour T-cell responses in a melanoma model. These cryogels can be delivered in a minimally invasive manner, bypass the need for genetic modification of transplanted cancer cells and provide sustained release of immunomodulators. Altogether, these findings indicate the potential for cryogels to serve as a platform for cancer cell vaccinations. Immune responses are induced in the organized, cytokine-rich environment of lymph nodes, which can be mimicked by biomaterials. Here the authors show that injectable sponge-like gels decorated with immunostimulatory factors attract dendritic cells and boost antitumour immune responses in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Lutz, M. B., Kukutsch, N., Ogilvie, A. L. J., Rößner, S., Koch, F., Romani, N., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00204-x · Cited by 2,966
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Self-citationTaking dendritic cells into medicine
Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,127
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
The extracellular matrix as a cell survival factor.
Meredith, J. E., Fazeli, B., & Schwartz, M. A. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.9.953 · Cited by 1,526
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Structure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
Inspiration and application in the evolution of biomaterials
Huebsch, N., & Mooney, D. J. (2009) · Nature · doi:10.1038/nature08601 · Cited by 855
Self-citationAguado, B. A., Mulyasasmita, W., Su, J., Lampe, K. J., & Heilshorn, S. C. (2012) · Tissue Engineering Part A · doi:10.1089/ten.tea.2011.0391 · Cited by 719
Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594
Shi, Y., Liu, C. H., Roberts, A. I., Das, J., Xu, G., Ren, G., Zhang, Y., Zhang, L., Yuan, Z. R., Tan, H. S. W., et al. (2006) · Cell Research · doi:10.1038/sj.cr.7310017 · Cited by 547
Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy
Swartz, M. A., Iida, N., Roberts, E. W., Sangaletti, S., Wong, M. H., Yull, F. E., Coussens, L. M., & DeClerck, Y. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0122 · Cited by 542
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., & Engleman, E. G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141226398 · Cited by 541
Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535
Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529
Injectable preformed scaffolds with shape-memory properties
Bencherif, S. A., Sands, R. W., Bhatta, D., Arany, P., Verbeke, C. S., Edwards, D. A., & Mooney, D. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211516109 · Cited by 499
Self-citationThe CD8+ dendritic cell subset
Shortman, K., & Heath, W. R. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00870.x · Cited by 487
Infection-mimicking materials to program dendritic cells in situ
Ali, O. A., Huebsch, N., Cao, L., Dranoff, G., & Mooney, D. J. (2009) · Nature Materials · doi:10.1038/nmat2357 · Cited by 434
Self-citationDr William Coley and tumour regression: a place in history or in the future
Hoption Cann, S. A., van Netten, J. P., & van Netten, C. (2003) · Postgraduate Medical Journal · doi:10.1093/postgradmedj/79.938.672 · Cited by 433
Dhodapkar, M. V., Sznol, M., Zhao, B., Wang, D., Carvajal, R. D., Keohan, M. L., Chuang, E., Sanborn, R. E., Lutzky, J., Powderly, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008068 · Cited by 365
van de Laar, L., Coffer, P. J., & Woltman, A. M. (2012) · Blood · doi:10.1182/blood-2011-11-370130 · Cited by 358
Josien, R., Li, H.-L., Ingulli, E., Sarma, S., R.Wong, B., Vologodskaia, M., Steinman, R. M., & Choi, Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.3.495 · Cited by 334
Chiang, C. L.-L., Benencia, F., & Coukos, G. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.02.004 · Cited by 247
Trial watch: Dendritic cell-based interventions for cancer therapy
Vacchelli, E., Vitale, I., Eggermont, A., Fridman, W. H., Fučíková, J., Cremer, I., Galon, J., Tartour, E., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 247
Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
Hu-Lieskovan, S., Robert, L., Homet Moreno, B., & Ribas, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.1377 · Cited by 199
Whole Cell Vaccines—Past Progress and Future Strategies
Keenan, B. P., & Jaffee, E. M. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.007 · Cited by 165
Trial watch: Dendritic cell-based interventions for cancer therapy
Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21494 · Cited by 156
Kleindienst, P., & Brocker, T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.2817 · Cited by 153
Sznol, M., Kluger, H. M., Callahan, M. K., Postow, M. A., Gordon, R. A., Segal, N. H., Rizvi, N. A., Lesokhin, A. M., Atkins, M. B., Kirkwood, J. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.lba9003 · Cited by 151
Ribas, A., Hodi, F. S., Kefford, R. F., Hamid, O., DAUD, A. I., Wolchok, J. D., Hwu, W., Gangadhar, T. C., Patnaik, A., Joshua, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba9000 · Cited by 147
Liu, Y., Liang, X., Joo, K., Hu, B., Fang, J., & Wang, P. (2014) · Biomacromolecules · doi:10.1021/bm501166j · Cited by 103
Kratky, W., Sousa, C. R. E., Oxenius, A., & Spörri, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108945108 · Cited by 101
Mouse models for melanoma: a personal perspective
Becker, J. C., Houben, R., Schrama, D., Voigt, H., Ugurel, S., & Reisfeld, R. A. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.00986.x · Cited by 93
Singh, A. K., Qin, H., Fernandez, I., Wei, J., Lin, J. X., Kwak, L. W., & Roy, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.008 · Cited by 87
Eggermont, A. M. M., Chiarion‐Sileni, V., Grob, J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba9008 · Cited by 77
Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?
Zacharski, L. R., & Sukhatme, V. P. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01110.x · Cited by 61
Davis, M. B., Vasquez-Dunddel, D., Fu, J. L., Albesiano, E., Pardoll, D., & Kim, Y. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3262 · Cited by 61
Materials based tumor immunotherapy vaccines
Li, A. W., & Mooney, D. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.008 · Cited by 57
Self-citationWhole-cell vaccines: A failure or a success waiting to happen?
Copier, J. P., & Dalgleish, A. G. (2010) · PubMed · Cited by 55
What Is a Good Model for Melanoma?
Herlyn, M., & Fukunaga‐Kalabis, M. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.441 · Cited by 47
Ali, O. A., Doherty, E. J., Mooney, D. J., & Emerich, D. F. (2011) · Biomatter · doi:10.4161/biom.1.1.16277 · Cited by 35
Self-citationVaccines for Melanoma and Renal Cell Carcinoma
Kaufman, H. L. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.011 · Cited by 31
Pharmacologically Triggered Hydrogel for Scheduling Hepatitis B Vaccine Administration
Gübeli, R. J., Schöneweis, K., Huzly, D., Ehrbar, M., Hamri, G. C., El‐Baba, M. D., Urban, S., & Weber, W. (2013) · Scientific Reports · doi:10.1038/srep02610 · Cited by 28
Caulfield, Fernández, F., Sousa, Lanĕ, Lee, & Hawrylowicz, C. M. (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00862.x · Cited by 27
Engineering T cells for cancer therapy
Mansoor, W., Gilham, D. E., Thistlethwaite, F. C., & Hawkins, R. E. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602839 · Cited by 26
Cited by
Designing hydrogels for controlled drug delivery
Li, J., & Mooney, D. J. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.71 · Cited by 4,832
Self-citationDelivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Zhao, X., Guo, B., Wu, H., Liang, Y., & Ma, P. X. (2018) · Nature Communications · doi:10.1038/s41467-018-04998-9 · Cited by 1,161
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Improving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628
Metadata
- Authors
- Bencherif, S. A., Warren Sands, R., Ali, O. A., Li, W. A., Lewin, S. A., Braschler, T. M., Shih, T.-Y., Verbeke, C. S., Bhatta, D., Dranoff, G., & Mooney, D. J.
- Venue
- Nature Communications
- Published
- 2015-08-12
- Volume
- 6
- Issue
- 1
- Pages
- 7556-7556
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W1854274831
- Cited by
- 416
- References
- 54
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.